Submitted by dcc on Fri, 2022-09-09 13:56 Study Title: A Phase 2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsCIRB: Pediatric CIRBLead Group: PEP-CTNStatus: ActiveReview Status: Available to Open
